269 results on '"Winn, Aaron N."'
Search Results
2. Racial and Ethnic Differences in Medication Initiation Among Adults Newly Diagnosed with Type 2 Diabetes
3. Medication delivery factors and adjuvant endocrine therapy adherence in breast cancer
4. Concurrent prescribing of opioids with other sedating medications after cancer diagnosis: a population-level analysis
5. Real-world implementation evaluation of an electronic health record-integrated consumer informatics tool that collects patient-generated contextual data
6. The Longer-Term Benefits and Harms of Glucagon-Like Peptide-1 Receptor Agonists: a Systematic Review and Meta-Analysis
7. Longer-term Benefits and Risks of Sodium-Glucose Cotransporter-2 Inhibitors in Type 2 Diabetes: a Systematic Review and Meta-analysis
8. Financial burden and medication adherence among near-poor older adults in a pharmaceutical assistance program
9. Commercial Versus Medicaid Insurance and Use of High-Priced Anticancer Treatments
10. The Role of Physician Professional Networks in Physicians’ Receipt of Pharmaceutical and Medical Device Industries’ Payments
11. Referral and Prescription Patterns for Female Patients With Urinary Incontinence.
12. Pharmaceutical industry payments and delivery of non-recommended and low value cancer drugs: population based cohort study
13. Gene Therapy Versus Common Care for Eligible Individuals With Sickle Cell Disease in the United States: A Cost-Effectiveness Analysis.
14. Identifying Heterogeneous Treatment Effects of Drug Policy in Quasi-experimental Settings
15. First-Line Therapy for Type 2 Diabetes With Sodium–Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists
16. Using Group-based Trajectory Models and Propensity Score Weighting to Detect Heterogenous Treatment Effects: The Case Study of Generic Hormonal Therapy for Women With Breast Cancer
17. Annals On Call - First-Line Drug Therapy for Type 2 Diabetes
18. Supplemental Nutrition Assistance Program (SNAP) Benefit Cycles and Student Disciplinary Infractions
19. Linking Costs and Survival in the Treatment of Older Adults With Chronic Myeloid Leukemia : An Analysis of SEER-Medicare Data From 1995 to 2007
20. Cost-Effectiveness of Autologous Hematopoietic Stem Cell Transplantation for Elderly Patients with Multiple Myeloma using the Surveillance, Epidemiology, and End Results–Medicare Database
21. Using Group-based Trajectory Models and Propensity Score Weighting to Detect Heterogeneous Treatment Effects: The Case Study of Generic Hormonal Therapy for Women With Breast Cancer
22. Value of innovation in hematologic malignancies: a systematic review of published cost-effectiveness analyses
23. Cost-Utility Analyses in Diabetes: A Systematic Review and Implications from Real-World Evidence
24. Twenty-first century house calls: a survey of ambulatory care providers to inform organisational telehealth strategy
25. First-Line Therapy for Type 2 Diabetes With Sodium–Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists
26. The Role of the FDA and Regulatory Approval of New Devices for Diabetes Care
27. Racial and Ethnic Differences in Medication Initiation Among Adults Newly Diagnosed with Type 2 Diabetes
28. Individualized Glycemic Control for U.S. Adults With Type 2 Diabetes: A Cost-Effectiveness Analysis
29. 886-P: Development and Validation of the Diabetes Outcome Model for the U.S. (DOMUS)
30. Untangling the Black-White mortality gap in endometrial cancer: a cohort simulation
31. The Real World Effectiveness of Hematopoietic Transplant Among Elderly Individuals With Multiple Myeloma
32. Longer-term Benefits and Risks of Sodium-Glucose Cotransporter-2 Inhibitors in Type 2 Diabetes: a Systematic Review and Meta-analysis
33. Analysis of Clinician and Patient Factors and Completion of Telemedicine Appointments Using Video
34. Personal Payments from Pharmaceutical Companies to Authors of Oncology Clinical Practice Guidelines
35. The Longer-Term Benefits and Harms of Glucagon-Like Peptide-1 Receptor Agonists: a Systematic Review and Meta-Analysis
36. Clinician burnout during the COVID-19 pandemic before vaccine administration
37. The cost, survival, and quality‐of‐life implications of guideline‐discordant imaging for prostate cancer
38. Comparison of Anticancer Medication Use and Spending Under US Oncology Parity Laws With and Without Out-of-Pocket Spending Caps
39. Cost-effectiveness of MODY genetic testing: translating genomic advances into practical health applications
40. An adapted two-step floating catchment area method accounting for urban–rural differences in spatial access to pharmacies
41. The costs of treating and not treating patients with chronic myeloid leukemia with tyrosine kinase inhibitors among Medicare patients in the United States
42. The cost, survival, and quality-of-life implications of guideline-discordant imaging for prostate cancer.
43. The Cost-Effectiveness of Personalized Genetic Medicine: The case of genetic testing in neonatal diabetes
44. Response to Strassels and Durham
45. Association of Current Opioid Use With Serious Adverse Events Among Older Adult Survivors of Breast Cancer
46. 1175-P: Racial Difference in Diabetes Medication Initiation
47. The impact of the use of opioids among older breast cancer survivors and adverse events.
48. Factors associated with adjuvant endocrine therapy adherence in non-metastatic breast cancer.
49. The association between drug industry payments and NCCN guideline panel membership.
50. The impact of generic aromatase inhibitors on initiation, adherence, and persistence among women with breast cancer: Applying multi‐state models to understand the dynamics of adherence
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.